WO2002064166A1 - Preparation permettant d'ameliorer la biodisponibilite des matieres bioactives et procede de preparation correspondant - Google Patents

Preparation permettant d'ameliorer la biodisponibilite des matieres bioactives et procede de preparation correspondant Download PDF

Info

Publication number
WO2002064166A1
WO2002064166A1 PCT/KR2002/000206 KR0200206W WO02064166A1 WO 2002064166 A1 WO2002064166 A1 WO 2002064166A1 KR 0200206 W KR0200206 W KR 0200206W WO 02064166 A1 WO02064166 A1 WO 02064166A1
Authority
WO
WIPO (PCT)
Prior art keywords
enhanced bioavailability
bioactive compounds
compounds according
group
peptides
Prior art date
Application number
PCT/KR2002/000206
Other languages
English (en)
Inventor
Seo-Young Jeong
Ick-Chan Kwon
Hesson Chung
Original Assignee
Korea Institute Of Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute Of Science And Technology filed Critical Korea Institute Of Science And Technology
Publication of WO2002064166A1 publication Critical patent/WO2002064166A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to a composition and a formulation to enhance bioavailability of bioactive materials and preparation method thereof. More particularly, the present invention relates to a composition comprising at least one monoglyceride, at least one emulsifier, organic solvents and aqueous solution and a liquid or powder formulation prepared by adding bioactive material with a low bioavailability to enhance bioavailability of bioactive materials and to acquire high encapsulation efficiency of the bioactive material and high storage stability for a long period of time and preparation method thereof.
  • Solubilization of materials can be applied to a variety of fields.
  • chemical processing where their catalysts, reactants, intermediates, etc. are water-insoluble materials
  • the solubilization of these materials will affect the yield and the direction of a given reaction.
  • Numerous Pharmaceutical compounds with good physiological activities are known to be insoluble in water and thus they have relatively low bioavailabilities. Because the solubilization of these Pharmaceutical compounds can simplify administration routes and increase pharmaceutical effects, the solubilization technology is essential in commercializing water-insoluble pharmaceuticals, and therefore extensive worldwide studies have been focused on developing the solubilization technology.
  • Cyclosporin and paclitaxel (Taxol ® ) are good Examples of water-insoluble Pharmaceutical compounds that cannot be administered alone due to their low solubilities.
  • Cyclosporin and paclitaxel are commercially available as pre-concentrates of Cremophor emulsion. These formulations can spontaneously form microemulsion upon dispersion in water (U.S. Pat. No. 5,438,072).
  • solubilizing formulations include emulsion or liposome, which uses lipid as a medium, and a polymeric nanoparticle or polymeric micelle, which uses a polymer as a medium (Langer, R. Nature, 392, 5-10, 1998).
  • lipid as a medium
  • the formulations using lipid as a medium are relatively advantageous in that their raw materials are biocompatible and thus they can be widely applied to medical fields including drug delivery systems.
  • the emulsions are heterogeneous mixture of oil and water by the use of emulsifiers.
  • the oil-in-water type emulsions composed of oil components dispersed in water, are widely used in solubilizing water-insoluble pharmaceutical compounds.
  • Liposome formulations consist of spherical lipid vesicles with lipid bilayers and water-insoluble Pharmaceutical compounds are enclosed within the lipid bilayer.
  • U.S. Pat. No. 5,531 ,925 discloses Cubosome®, another type of formulation using lipid as a solubilization medium, which was first developed by Swedish scientists in early 1990s. Cubosome® is prepared by dispersing the hydrated lipid cubic phase in water. The interior of Cubosome® comprises cubic phase wherein lipid and water components constitute continuous but separate three-dimensional channels, and there exists an interface between lipid headgroup and water.
  • Cubosome® could be advantageous over the conventional emulsion type or liposome type formulations, which only allow solubilization of hydrophobic and hydrophilic Pharmaceutical compounds, respectively, in that they can solubilize amphiphilic Pharmaceutical compounds as well as hydrophobic and hydrophilic Pharmaceutical compounds.
  • Cubosome® can be formed by first forming a very viscous liquid cubic phase by adding water and an emulsifier to monoglyceride, and then by dispersing the mixture in water.
  • Cubosome® has average particle size of as large as several micrometers in diameter with the aid of emulsifiers. Since it is preferential to have submicron-sized particles for the solubilization of Pharmaceutical compounds, it is also possible to obtain submicron-sized particles by applying mechanical forces such as microfluidization. Preparing submicron-sized Cubosome® particles by means of a mechanical force, however, may result in physicochemical instability of the enclosed materials or the constituting ingredients of the formulations due to high energy and high temperature accompanying the mechanical process.
  • the formulation process may also incur hydrolysis and oxidization of constituting ingredients because the enclosed materials or the constituting ingredients of the formulations may be vigorously mixed with air during the microfluidization process.
  • the dispersed Cubosome® prepared by the microfluidization process may experience the instability of the dispersion system after a prolonged storage and subsequently result in phase separation due to aggregation of particles.
  • Cubosome® type formulations have advantageous properties as described above over the conventional type of formulations, they also have disadvantages that they cannot encapsulate the thermally labile pharmaceutical compounds. Also, the physical and chemical stability of the formulation need to be improved greatly to provide a successful drug delivery system.
  • Peptide and proteins are physiologically active compounds and can be used as therapeutics with specific functions when compared to the molecules with smaller molecular weights. Proteins, however, cannot be orally administered since they are digested into amino acids by proteases inside the gastro-intestinal tract and lose the physiologically activity. The clearance rate of pharmaceutical proteins is also high in the blood stream when injected, causing great difficulties in administering the protein drugs.
  • Insulin is a drug that must be administered to the insulin dependent diabetes mellitus (IDDM) patients.
  • IDDM insulin dependent diabetes mellitus
  • IDDM insulin dependent diabetes mellitus
  • IDDM insulin dependent diabetes mellitus
  • IDDM insulin dependent diabetes mellitus
  • Successful oral insulin formulation will bring a revolutionary advancement in the treatment of IDDM.
  • many pharmaceutical companies and research groups have endeavored to make an oral insulin formulation with high bioavailability. Due to the limitations in the absorption of insulin in the gastrointestinal tract, however, it is only the beginning
  • peptide delivery systems have been developed. For instance, insulin was encapsulated inside liposomes or polymeric microspheres or administered together with protease inhibitors to prohibit the degradation of insulin.
  • the oral bioavailability could not be enhanced much, however, since the carriers such as liposomes have a relatively low encapsulation efficiency, and the insulin can also degrade during the encapsulation process.
  • Cyclosporin is the only peptide drug that can be administered orally. Cyclosporin is commercially available as pre- concentrates of Cremophor emulsion which can spontaneously form microemulsion upon dispersion in water (U.S. Pat. No. 5,438,072). There are no other oral peptide or protein formulations in the market, however, excepting the oral cyclosporin formulation. The main difficulty arises from the fact that peptide or protein is hard to be encapsulated inside a carrier, can be easily denatured and loses the pharmaceutical activity upon the storage even if it can be encapsulated in the carrier.
  • the present inventors have developed a solubilizing composition for insoluble drugs comprising a monoglyceride, an emulsifier and an organic solvent (Korea patent application 2000-12465) to overcome the problems of poor oral bioavailability.
  • the above solubilizing composition solubilizes various compounds, especially insoluble and amphiphilic substances effectively.
  • This liquid formulation can be easily dispersed in water, by shaking or vortexing, to form a dispersion of particles of less than 500 nm.
  • the above solubilizing composition can encapsulate most of the drugs efficiently even though the encapsulating efficiency depends on many factors including the molecular weight or hydrophobicity of the drugs. Peptides or proteins, however, cannot be solubilized in the above solubilizing composition since they do not mix with any of the components and forms precipitations.
  • the inventors of the present invention finally succeeded in preparing a homogeneous liquid composition comprising monoglycerides, emulsifiers, organic solvents, and water for enhanced bioavailability of bioactive compounds.
  • the present inventors also prepared a composition for enhanced bioavailability of bioactive compounds by adding and aqueous solution of peptide, protein or water-soluble polymers in the mixture of monoglycerides, emulsifier and organic solvent.
  • bioactive compounds including peptides, proteins and drugs for injection or external application by solubilizing and delivering the bioactive compounds efficiently inside the body and the preparation method thereof.
  • Another object of the present invention is to provide a powder composition for enhanced bioavailability of bioactive compounds prepared from the above liquid composition for enhanced bioavailability of bioactive compounds.
  • Yet another object of the present invention is to provide a powder formulation for enhanced bioavailability of bioactive compounds prepared by adding at least one bioactive compound with a low bioavailability into the above composition for enhanced bioavailability of bioactive compounds.
  • the present invention relates to a liquid composition for enhanced bioavailability of bioactive compounds comprising 9-90% by weight of at least one monoglyceride to increase bioavailability, 0.01-80 % by weight of at least one emulsifier, 0.01- 10 % by weight of aqueous solution to solubilize the bioactive compounds with a low bioavailability and 0.001-90.9 % by weight of at least one organic solvent.
  • the above monoglycerides are preferably selected from the group consisting of one or more saturated or an unsaturated monoglycerides having 10 - 22 carbon atoms in the hydrocarbon chain.
  • the content of the monoglycerides in the total amount of the liquid formulation is preferably 9 - 90 % by weight.
  • Monoglycerides is selected preferably from a group of consisting of monoolein, monopalmitolein, monomyristolein, monoelaidin, and monoerucin, and more preferably monoolein.
  • the emulsifier is preferably selected from the group consisting of a phospholipid, a sphingolipid, a non-ionic surfactant, an anionic surfactant, a cationic surfactant and bile acid.
  • the content of the emulsifier in the total amount of the liquid formulation is preferably 0.01 - 80 % by weight.
  • the phospholipid used as the above emulsifier is preferably selected from the group consisting of a phosphatidylcholine (PC) and its derivative, a phosphatidylethanolamine (PE) and its derivative, a phosphatidylsehne (PS) and its derivative and a polymeric lipid wherein a hydrophilic polymer is conjugated to the lipid headgroup.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • PS phosphatidylsehne
  • the sphingolipid used as the above emulsifier is preferably selected from the group consisting of a ceramide, a cerebroside and a sphingomyelin.
  • the non-ionic surfactant used as the above emulsifier is preferably selected from the group consisting of a poloxamer (Pluronic: polyoxyethylene- polyoxypropylene copolymer), a sorbitan ester (Span), a polyoxyethylene sorbitan (Tween) and a polyoxyethylene ether (Brij).
  • the anionic surfactant used as the above emulsifier is preferably selected from the group consisting of a phosphatidylsehne (PS) and its derivative, a phosphatidic acid (PA) and its derivative and sodium dodecyl sulfate (SDS).
  • PS phosphatidylsehne
  • PA phosphatidic acid
  • SDS sodium dodecyl sulfate
  • the cationic surfactant used as the above emulsifier is preferably selected from the group consisting of 1 ,2- dioleyl-3-trimethylammonium propane (DOTAP), dimethyldioctadecylammonium bromide (DDAB), N-[1- (1 ,2-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1 ,2-
  • DOTAP dioleyl-3-trimethylammonium propane
  • DDAB dimethyldioctadecylammonium bromide
  • DOTMA N-[1- (1 ,2-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
  • DOEPC dioleyl-3-ethylphosphocholine
  • the bile acid used as the above emulsifier is preferably selected from the group consisting of cholic acid, its salt and derivatives; deoxycholic acid, its salt and derivatives; ursodeoxycholic acid, its salt and derivatives; chenocholic acid, its salt and derivatives; and lithocholic acid, its salt and derivatives.
  • the aqueous solution to solubilize the bioactive compounds with a low bioavailability is preferably selected from the group consisting of water, an acidic solution including hydrochloric acid solution, phosphoric acid and acetic acid solution, a basic solution including sodium bicarbonate solution, and a biochemical buffer solution including phosphate buffered saline (PBS).
  • the content of the aqueous solution in the total amount of the liquid formulation is preferably 0.01 - 10 % by weight.
  • the organic solvent is selected from the group consisting of alcohol, ethyleneglycol, propylene glycol, polyethyleneglycol, dimethylsulfoxide, and the mixture of these solvents.
  • the organic solvent can be preferably selected from the group consisting of acetone, chloroform, benzene, toluene, acetonitrile, alcohols including octanol and the mixture of these solvents, when the said liquid composition is not used for in vivo drug delivery systems.
  • liquid formulation is preferably 1 ⁇ 90 % by weight.
  • the method of preparing the composition according to the present invention for enhanced bioavailability of bioactive compounds comprises the steps of:
  • CO- lt is preferable that the organic solvent in the first step of the above preparation method is selected from the group consisting of alcohol, ethyleneglycol, propylene glycol, polyethyleneglycol, dimethylsulfoxide, [or] and the mixture of these solvents.
  • the organic solvent in the second step of the above preparation method is selected from the group consisting of alcohol, ethyleneglycol, propylene glycol, polyethyleneglycol, dimethylsulfoxide, and the mixture of these solvents.
  • the organic solvent can be preferably selected from the group consisting of acetone, chloroform, benzene, toluene, acetonitrule, alcohols including octanol and the mixture of these solvents, when the said liquid composition is not used for in vivo drug delivery systems.
  • the present invention relates to a powder composition for enhanced bioavailability of bioactive compounds manufactured by lyophilization of the dispersion of the above liquid formulation for enhanced bioavailability of bioactive compounds by adding 0-30% (w/v) of a cryoprotectant.
  • the method of preparing the powder composition according to the present invention for enhanced bioavailability of bioactive compounds comprises the steps of:
  • step (2) 2) lyophilizing the dispersion in step (1) in the presence of cryoprotectant to prepare the powder formulation.
  • a cryoprotectant may be used to prevent the morphological changes of the particles in the dispersion of the above formulation during lyophilization, and it is preferable to add it less than 30% (w/v) to the liquid formulation.
  • cryoprotectant examples include sugars such as mannitol or trehalose, amino acids such as arginine, and proteins such as albumin.
  • the liquid and powder composition of the present invention can be easily dispersed in water mediated by such a minimal mechanical aid as a simply shaking with hands.
  • the size of particles is approximately 200 nm in general and can become as large as 500 nm depending on the property of a given emulsifier.
  • the present invention also provides formulations for enhanced bioavailability of bioactive materials as a drug delivery system.
  • the present invention provides a liquid and a powder formulation for enhanced bioavailability of bioactive materials and the preparation method thereof.
  • a liquid formulation for enhanced bioavailability of bioactive compounds according to the present invention comprises 0.001 - 50 % by weight of at least one bioactive compound with a low bioavailability as an
  • active ingredient 9 — 90 % by weight of at least one monoglyceride compound, 0.01-80 % by weight of at least one emulsifier, 0.01 - 10 % by weight of aqueous solution to solubilize the bioactive compound with a low bioavailability and 0.001 - 90 % by weight of organic solvent.
  • the kinds of monoglyceride compound, emulsifier, aqueous solution and organic solvent are identical as mentioned above.
  • peptides that can be used in the present invention include adrenocorticotropic hormone (ACTH) and its fragments, angiotensin and its related peptides, antibodies and their fragments, antigens and their fragments, atrial natriuretic peptides, bioadhesive peptides, Bradykinins and their related peptides, calcitonins and their related peptides, cell surface receptor protein fragments, chemotactic peptides, cyclosporins, cytokines, Dynorphins and their related peptides,
  • ACTH adrenocorticotropic hormone
  • angiotensin and its related peptides antibodies and their fragments, antigens and their fragments
  • atrial natriuretic peptides bioadhesive peptides
  • Bradykinins and their related peptides calcitonins and their related peptides
  • cell surface receptor protein fragments chemotact
  • enzyme inhibitors enzyme inhibitors, fibronectin fragments and their related peptides, gastrointestinal peptides, growth hormone releasing peptides, immunostimulating peptides, insulins and insulin-like growth factors, interleukins, luthenizing hormone releasing hormones (LHRH) and their related peptides, melanocyte stimulating hormones and their related peptides, nuclear localization signal related peptides, neurotensins and their related peptides, neurotransmitter peptides, opioid peptides, oxytocins, vasopressins and their related peptides, parathyroid hormone and its fragments, protein kinases and their related peptides, somatostatins and their related peptides, substance P and its related peptides, transforming growth factors (TGF) and their related peptides, tumor necrosis factor fragments, toxins and toxoids.
  • TGF transforming growth factors
  • Insulin as a peptide is preferably selected from a group consisting of a bovine pancreatic insulin, a human insulin, a human recombinant insulin, a porcine pancreatic insulin, an arg-insulin, an insulin-biotin, an insulin-FITC, LysPro (Eli Lilly) and a polyethylene glycol-insulin, (PEG-insulin).
  • the content of insulin in the total amount of the liquid formulation is preferably 0.01 - 20 % by weight.
  • the formulation of the present invention can comprise functional peptides such as anticancer peptides including angiostatins, antihypertension peptides, anti-blood clotting peptides, and antimicrobial peptides.
  • anticancer peptides including angiostatins, antihypertension peptides, anti-blood clotting peptides, and antimicrobial peptides.
  • the formulation of the present invention can comprise proteins such as immunoglobulins, angiogenins, bone morphogenic proteins, chemokines, colony stimulating factors (CSF) and their related proteins, cytokines, growth factors, interferons, interleukins, leptins, leukemia inhibitory factors, stem cell factors, transforming growth factors and tumor necrosis factors.
  • proteins such as immunoglobulins, angiogenins, bone morphogenic proteins, chemokines, colony stimulating factors (CSF) and their related proteins, cytokines, growth factors, interferons, interleukins, leptins, leukemia inhibitory factors, stem cell factors, transforming growth factors and tumor necrosis factors.
  • the above formulations can enclose a hydrophilic, a hydrophobic and an amphiphilic compound, especially a compound with a high molecular weight as a Pharmaceutical compound.
  • these Pharmaceutical compounds that can be used in the present invention are antivirals, steroidal anti-inflammatory drugs (SAID), non-steroidal anti-inflammatory drugs (NSAID), antibiotics, antifungals, vitamins, hormones, retinoic acid, prostaglandins, prostacyclins, anticancer drugs, antimetabolitic drugs, miotics, cholinergics, adrenergic antagonists, anticonvulsants, antianxiety agents, major tranquilizers, antidepressants, anesthetics, analgesics, anabolic steroids, estrogens, progesterones, glycosaminoglycans, polynucleotides, immunosuppressants and immunostimulants.
  • SAID steroidal anti-inflammatory drugs
  • NSAID non-steroidal anti-inflammatory drugs
  • antibiotics antibiotics
  • the above formulations can solubilize a hydrophilic and an amphiphilic polymer.
  • these polymers that can be used in the present invention are chitosan, alginic acid, alginate, hyaluronic acid, hyaluronate, polyethylene glycol and other functional polymers.
  • the preparation method of the above liquid formulation for enhanced bioavailability of bioactive compounds comprises the steps of:
  • step (1) After the evaporation, a trace of more than 0.001 % of volatile organic solvent of the total formulation is still present in the liquid formulation since the evaporation process does not require high vacuum.
  • a solvent mixture is used instead of a single solvent, only the volatile solvent is evaporated leaving involatile solvent in the final formulation.
  • the organic solvent in the first step of the above preparation method is selected from the group consisting of alcohol, ethyleneglycol, propylene glycol, polyethyleneglycol, dimethylsulfoxide, and the mixture of these solvents.
  • the organic solvent in the second step of the above preparation method is selected from the group consisting of alcohol, ethyleneglycol, propylene glycol, polyethyleneglycol, dimethylsulfoxide, and the mixture of these solvents.
  • the organic solvent can also be selected from the group consisting of acetone, chloroform, benzene, toluene, acetonitrule, alcohols including octanol when the said liquid composition is not used for in vivo drug delivery systems.
  • amount of the liquid formulation is preferably 0.001 — 90 % by weight.
  • the present invention provides a powder formulation for enhanced bioavailability of bioactive compounds manufactured by lyophilization of the dispersion of the above liquid formulation by adding 0-30% (w/v) of a cryoprotectant.
  • the preparation method of the above powder formulation comprises the steps of:
  • step (2) 2) lyophilizing said dispersion in step (1) in the presence of cryoprotectant.
  • a cryoprotectant may be used to prevent the morphological changes in the dispersion of the above formulation during lyophilization, and it is preferred to add it less than 30% (w/v) to the liquid formulation.
  • Preferred examples of a cryoprotectant include sugars such as mannitol or trehalose, amino acids such as arginine, and proteins such as albumin.
  • the liquid and powder formulation of the present invention can be easily dispersed in water mediated by such a minimal mechanical aid as a simply shaking with hands.
  • the size of particles is approximately 200 nm in general and can become as large as 500 nm depending on the property of a given pharmaceutical compounds or an emulsifier.
  • the constituting ingredients of and pharmaceutical compound in the particles are not degraded since a strong mechanical force is not required in generating the particles.
  • the above powder formulation dispersed easily in water before the intake.
  • the powder formulation can be dispersed in water for injection.
  • the formulations according to the present invention can be stored at room temperature in a sealed state for a long period of time without undergoing phase separation or the change in properties of the formulations.
  • the powder formulation is desirable because it does not contact with an organic solvent or moisture.
  • formulations of the present invention can be used as an
  • BSA bovine serum albumin
  • the size the polydispersity of the emulsion particles were measured by Photon Correlation spectroscopy (QELS method) using Malvern Zetasizer (Malvern Instruments Limited, England), and the polydispersity is a variance of the particle size in a logarithmic scale of a log-normal distribution function of the particle size.
  • the average particle size and polydispersity were obtained by measuring a given formulation three times (Orr, Encyclopedia of emulsion technology, 1 , 369- 404, 1985). This method was used in measuring the particle size and the polydispersity throughout the following Examples.
  • the above liquid formulations were dispersed well in water, and the average particle size and polydispersity were about 296.2 nm and 0.164, respectively.
  • Example 2 Preparation of Powder Formulation Containing Bovine Serum Albumin
  • 0.1 ml of the liquid formulation Containing Bovine Serum Albumin obtained in Example 1 1 ml of 5 % trehalose aqueous solution was added and solubilized completely by shaking. The mixture was lyophilized to prepare a powder formulation. The average particle size and polydispersity of the dispersion of the powder formulation were determined after dispersing approximately 3 mg of the above powder formulation in 3 ml of water or 0.01 M sodium deoxycholate as described in Example 1-2.
  • the above powder formulation was dispersed well in water, and, as indicated in the following table 1 , the average particle size and polydispersity of the dispersion of the powder formulation were 483.6 nm and 0.461 , respectively, in water and 170.0 nm and 0.276, respectively, in 0.01 M sodium deoxycholate.
  • liquid formulation were determined after dispersing approximately 10 ⁇ l or 75
  • the above formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation were 303.9 nm and 0.185, respectively, in water and 175.2 nm and 0.377, respectively, in 0.01 M sodium deoxycholate.
  • the encapsulation efficiency of tetanus toxoid was determined as described in Example 1-2 except that the
  • the pneumococcal surface adhesin A (hereafter referred to "PsaA") dissolved in water was concentrated by using Sep-Pak Cartridges (Waters) to 0.5 mg/ml in methanol. In 1 ml of methanol, 10 mg of monoolein and 2 mg Pluronic F-68 or Pluronic F-127 were dissolved. The mixture was heated to
  • liquid formulation were determined after dispersing approximately 10 ⁇ l of the
  • Example 3 above liquid formulation in 3 ml of water, respectively, as described in Example 1-2.
  • the above formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation are summarized in Table 3.
  • the encapsulation efficiency of PsaA was determined as described in Example 1-2 and was ca. 50 %.
  • Example 2 In 0.1 ml of the liquid formulation Containing PsaA obtained in Example 1 , 1 ml of 5 % trehalose aqueous solution was added and solubilized completely by shaking. The mixture was lyophilized to prepare a powder formulation. The average particle size and polydispersity of the dispersion of the powder formulation were determined after dispersing approximately 3 mg of the above powder formulation in 3 ml of water or 0.01 M sodium deoxycholate as described in Example 1-2.
  • liquid formulation were determined after dispersing approximately 10 ⁇ l of the
  • the above formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation were 209.2 nm and 0.279, respectively.
  • the encapsulation efficiency of calcitonin was determined as described in Example 1-2 and was ca. 50 %.
  • a liquid insulin formulation was obtained by using the same procedure as described in Example 6 except that 3.0 mg of a growth hormone (somatotropin, from human pituitaries, 2 I.U./mg, Sigma) was used instead of calcitonin.
  • a growth hormone somatotropin, from human pituitaries, 2 I.U./mg, Sigma
  • the average particle size and polydispersity of the dispersion of the liquid formulation were determined after dispersing approximately 10 ⁇ l of the
  • the above formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation were 234.9 nm and 0.224, respectively.
  • the encapsulation efficiency of PsaA was determined as described in Example 1-2 and was ca. 70 %.
  • liquid formulation were determined after dispersing approximately 10 ⁇ l of the above liquid formulation in 3 ml of water, respectively, as described in Example 1-2.
  • the above formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation were 333.2 nm and 0.316, respectively.
  • the encapsulation efficiency of blue dextran was determined as described in Example 1-2 and was ca. 90 %.
  • the dispersion of the liquid and powder formulation according to the present invention has a particle size of less than 500 nm, a high solubilizing power of drugs and a high encapsulation efficiency of drugs.
  • the formulations according to the present invention can solubilize and encapsulate bioactive compounds with a low bioavailability such as peptides or proteins stably and also generate homogeneous particles less than 500 nm when dispersed in water. Moreover, the formulations can be easily dispersed in water without any mechanical aid, and problems such as phase separation, hydrolysis and oxidation, during long-term storage, can be prevented thus being suitable for use in drug delivery system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des préparations permettant d'améliorer la biodisponibilité de matières bioactives et un procédé de préparation correspondant. Plus précisément, cette invention se rapporte à une composition contenant au moins un monoglycéride, au moins un émulsifiant, des solvants organiques, une solution aqueuse, une préparation liquide et en poudre préparée par addition de matières bioactives présentant une faible biodisponibilité afin d'améliorer la biodisponibilité de matières bioactives et d'obtenir une grande capacité d'encapsulation des matières bioactives et une stabilité de stockage élevée sur une longue période. L'invention porte aussi sur un procédé de préparation correspondant.
PCT/KR2002/000206 2001-02-13 2002-02-08 Preparation permettant d'ameliorer la biodisponibilite des matieres bioactives et procede de preparation correspondant WO2002064166A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2001-0007125 2001-02-13
KR1020010007125A KR20020066778A (ko) 2001-02-13 2001-02-13 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법

Publications (1)

Publication Number Publication Date
WO2002064166A1 true WO2002064166A1 (fr) 2002-08-22

Family

ID=19705697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2002/000206 WO2002064166A1 (fr) 2001-02-13 2002-02-08 Preparation permettant d'ameliorer la biodisponibilite des matieres bioactives et procede de preparation correspondant

Country Status (2)

Country Link
KR (1) KR20020066778A (fr)
WO (1) WO2002064166A1 (fr)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066014A2 (fr) * 2001-02-20 2002-08-29 The Procter & Gamble Company Compositions de cristal liquide cubique et procédé d'élaboration
EP1578325A2 (fr) * 2002-12-31 2005-09-28 Perricone, Nicholas V., Dr. Compositions stables pour une administration de medicament topique
WO2006032386A1 (fr) * 2004-09-22 2006-03-30 Merck Patent Gmbh Lyophilisat contenant du n-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamide
WO2007011171A1 (fr) * 2005-07-21 2007-01-25 Mediplex Corp. Formulation médicamenteuse contenant un agent solubilisant pour améliorer la solubilité, l’absorption et la perméabilité
EP1915986A1 (fr) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Fomulations lipidiques comprenant des facteurs de croissance
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
US8119690B2 (en) 2007-02-15 2012-02-21 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8198324B2 (en) 2007-03-20 2012-06-12 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
WO2014021694A1 (fr) * 2012-08-03 2014-02-06 서울대학교 산학협력단 Composition visant à prévenir et traiter des maladies liées aux os
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8846046B2 (en) 2002-10-24 2014-09-30 Abbvie Biotechnology Ltd. Low dose methods for treating disorders in which TNFα activity is detrimental
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2014160047A3 (fr) * 2013-03-13 2014-11-20 Transdermal Biotechnology, Inc. Systèmes et procédés pour l'administration de peptides
US8911741B2 (en) 2002-08-16 2014-12-16 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US20150327539A1 (en) * 2013-03-15 2015-11-19 Truckee Applied Genomics, Llc Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US11166933B2 (en) 2018-05-03 2021-11-09 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US11478443B2 (en) 2018-02-07 2022-10-25 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN115444865A (zh) * 2022-08-04 2022-12-09 重庆极泽生物科技有限公司 一种转化熊胆粉底物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
KR20040033380A (ko) * 2002-10-14 2004-04-28 주식회사 엘지생활건강 경피 약물전달시스템
US20070021325A1 (en) * 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
JP6563922B2 (ja) * 2013-11-14 2019-08-21 リピドール エービー ホスファチジルコリンを含む噴霧可能な局部用キャリアー及び組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006043A1 (fr) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Formulation autoemulsifiante pour composes lipophiles
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
WO2001068139A1 (fr) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilisant des agents insolubles dans l'eau, et procede de preparation correspondant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
WO1999006043A1 (fr) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Formulation autoemulsifiante pour composes lipophiles
WO2001068139A1 (fr) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilisant des agents insolubles dans l'eau, et procede de preparation correspondant

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066014A3 (fr) * 2001-02-20 2003-09-04 Procter & Gamble Compositions de cristal liquide cubique et procédé d'élaboration
WO2002066014A2 (fr) * 2001-02-20 2002-08-29 The Procter & Gamble Company Compositions de cristal liquide cubique et procédé d'élaboration
US9060925B2 (en) 2002-05-31 2015-06-23 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US9302011B2 (en) 2002-08-16 2016-04-05 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-α associated disorders
US9295725B2 (en) 2002-08-16 2016-03-29 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US8911741B2 (en) 2002-08-16 2014-12-16 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US8916157B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8932591B2 (en) 2002-08-16 2015-01-13 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US9272042B2 (en) 2002-08-16 2016-03-01 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9272041B2 (en) 2002-08-16 2016-03-01 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9289497B2 (en) 2002-08-16 2016-03-22 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9220781B2 (en) 2002-08-16 2015-12-29 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US8940305B2 (en) 2002-08-16 2015-01-27 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8916158B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US9327032B2 (en) 2002-08-16 2016-05-03 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9732152B2 (en) 2002-08-16 2017-08-15 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9738714B2 (en) 2002-08-16 2017-08-22 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9114166B2 (en) 2002-08-16 2015-08-25 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US9750808B2 (en) 2002-08-16 2017-09-05 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US9950066B2 (en) 2002-08-16 2018-04-24 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US8846046B2 (en) 2002-10-24 2014-09-30 Abbvie Biotechnology Ltd. Low dose methods for treating disorders in which TNFα activity is detrimental
EP1578325A2 (fr) * 2002-12-31 2005-09-28 Perricone, Nicholas V., Dr. Compositions stables pour une administration de medicament topique
EP1578325B1 (fr) * 2002-12-31 2011-04-27 Transdermal Biotechnology, Inc. Compositions stables pour une administration de medicament topique
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
WO2006032386A1 (fr) * 2004-09-22 2006-03-30 Merck Patent Gmbh Lyophilisat contenant du n-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamide
WO2007011171A1 (fr) * 2005-07-21 2007-01-25 Mediplex Corp. Formulation médicamenteuse contenant un agent solubilisant pour améliorer la solubilité, l’absorption et la perméabilité
EP1915986A1 (fr) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Fomulations lipidiques comprenant des facteurs de croissance
US9480649B2 (en) 2006-10-23 2016-11-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Lipid microparticle growth factor formulations
WO2008049588A1 (fr) * 2006-10-23 2008-05-02 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Formulations lipidiques de facteurs de croissance
US8329747B2 (en) 2007-02-15 2012-12-11 Centro de Recherche sur les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US9233915B2 (en) 2007-02-15 2016-01-12 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8119690B2 (en) 2007-02-15 2012-02-21 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US9925165B2 (en) 2007-03-20 2018-03-27 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8198324B2 (en) 2007-03-20 2012-06-12 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8222295B2 (en) 2007-03-20 2012-07-17 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US9101563B2 (en) 2007-03-20 2015-08-11 Scf Pharma Inc Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
US8722737B2 (en) 2007-03-20 2014-05-13 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
US9480660B2 (en) 2007-03-20 2016-11-01 Scf Pharma Inc. Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof
US11167030B2 (en) 2007-11-30 2021-11-09 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US11191834B2 (en) 2007-11-30 2021-12-07 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US9085619B2 (en) 2007-11-30 2015-07-21 Abbvie Biotechnology Ltd. Anti-TNF antibody formulations
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9517179B2 (en) 2011-03-17 2016-12-13 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9937202B2 (en) 2011-03-17 2018-04-10 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
WO2014021694A1 (fr) * 2012-08-03 2014-02-06 서울대학교 산학협력단 Composition visant à prévenir et traiter des maladies liées aux os
US9844565B2 (en) 2012-09-19 2017-12-19 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9480709B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9198933B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9198970B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9198932B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9198930B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US10034898B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9295638B2 (en) 2012-09-19 2016-03-29 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US10034896B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9198853B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US10034897B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9968635B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9968634B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9950004B2 (en) 2012-09-19 2018-04-24 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9198931B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9827266B2 (en) 2012-09-19 2017-11-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9795632B2 (en) 2012-09-19 2017-10-24 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9480710B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9205043B2 (en) 2012-09-19 2015-12-08 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9480706B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9198854B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9480705B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9480708B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9480711B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9480707B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
WO2014160047A3 (fr) * 2013-03-13 2014-11-20 Transdermal Biotechnology, Inc. Systèmes et procédés pour l'administration de peptides
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9949474B2 (en) 2013-03-15 2018-04-24 Truckee Applied Genomics, Llc Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
US20150327539A1 (en) * 2013-03-15 2015-11-19 Truckee Applied Genomics, Llc Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
US10772318B2 (en) 2013-03-15 2020-09-15 Truckee Applied Genomics, Llc Methods and reagents for maintaining the visability of cancer cells in surgically removed tissue
US9445586B2 (en) * 2013-03-15 2016-09-20 Truckee Applied Genomics, Llc Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
US9565852B2 (en) 2013-03-15 2017-02-14 Truckee Applied Genomics, Llc Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US11478443B2 (en) 2018-02-07 2022-10-25 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US11701337B2 (en) 2018-02-07 2023-07-18 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US11166933B2 (en) 2018-05-03 2021-11-09 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN115444865A (zh) * 2022-08-04 2022-12-09 重庆极泽生物科技有限公司 一种转化熊胆粉底物及其制备方法

Also Published As

Publication number Publication date
KR20020066778A (ko) 2002-08-21

Similar Documents

Publication Publication Date Title
WO2002064166A1 (fr) Preparation permettant d'ameliorer la biodisponibilite des matieres bioactives et procede de preparation correspondant
WO2002064115A1 (fr) Formulation pour l'administration d'insuline et procede de preparation de cette formulation
AU2012302422B2 (en) Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
JP3932397B2 (ja) 薬物を含むキュボソーム粒子製造用液状剤形とキュボソーム粒子粉末剤形及びそれらの製造方法
US9526788B2 (en) Pharmaceutical lipid compositions
AU2004305395B2 (en) Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
US20170189532A1 (en) Phospholipid depot
US20100034880A1 (en) Pharmaceutical compositions based on a microemulsion
AU2012260821B2 (en) Controlled release peptide formulations
JP2012006934A (ja) 口腔及び経肺投与用ミセル薬学的組成物
WO2009092291A1 (fr) Système d'administration de médicament, son procédé de préparation et d'utilisation
WO2011086093A2 (fr) Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
AU2013265210B2 (en) Somatostatin receptor agonist formulations
CN102113996A (zh) 一种含有蛋白质或多肽的口服制剂、其制备方法及用途
KR20050081092A (ko) 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
WO2023041588A1 (fr) Nouvelle formulation de lipopeptides
Souto et al. Lipid Matrix Nanoparticles in Diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP